S&P Futures
4,565.75 -10.75 (-0.23%) Dow Futures
36,207.00 -61.00 (-0.17%) Nasdaq Futures
15,823.00 -46.00 (-0.29%) Russell 2000 Futures
1,880.30 -4.60 (-0.24%) Crude Oil
73.10 +0.06 (+0.08%) Gold
2,049.70 +7.50 (+0.37%)
Mustang Bio, Inc. (MBIO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.4400 |
| Open | 1.4800 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 900 |
| Day's Range | 1.4000 - 1.4800 |
| 52 Week Range | 1.2500 - 11.0850 |
| Volume | |
| Avg. Volume | 83,201 |
| Market Cap | 13.365M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MBIO
Related Research
- Mustang Bio, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat3 years agoMorningstar
- GlobeNewswire
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “I
- GlobeNewswire
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
Updated interim data from Mustang’s multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patientsWORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that interi
- GlobeNewswire
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the purchase and sale of 2,588,236 of its shares of com
